(Note: This is a data heavy piece. It is written as a counter argument to a comment that called the original post stupid, so I have gone deep into the annual report, cash flow statements, warrant mechanics, and share count math. Hope it is worth your time.

I am adding a compressed version in the comments with the exact parameters you need to check for dilution in any company you hold. If the full piece feels dense, start there)

Every IPO has a story. And stories are designed to seduce. That is why Buffett and Munger have always stayed away from IPOs. Their argument was simple: most of these instruments are designed to take value from retail investors, not give it to them.

This post is about exactly that. The dilution mental model. And how it integrates with the IPO mental model to show you what is actually happening to your ownership while the story is playing out.

Ratnaveer Precision Engineering is just the working example here. But once you see the pattern, you can map it on any company you hold right now.

That is the point of this post. Not Ratnaveer. The pattern.

The original post on Ratnaveer is here if you missed it: A promoter built a private bank inside his listed company

Before the IPO there were 3.47 crore shares in existence. Today there are 6.82 crore shares. After the upcoming rights issue there will be roughly 8.56 crore shares.

Your share count has not changed. The total share count has nearly tripled. Your ownership of this company has been cut to less than half of what it was on listing day, without you selling a single share.

That is dilution. And this is how it happened.

Chapter 1: Before the IPO

Two pre-IPO placements happened quietly in the months before listing.

• December 2022: shares sold to select investors at Rs 67 per share.
• January 2023: shares sold to select investors at Rs 72 per share.

Ten months later the IPO price was Rs 98.

The people who got in at Rs 67 and Rs 72 made 35 to 46 percent before the IPO even opened. Retail investors who applied at Rs 98 were already buying at a premium to these early insiders. The game started before most people knew there was a game.

And in November 2022, ten months before listing, the company changed its name from Ratnaveer Metals to Ratnaveer Precision Engineering.

Same products and just a new costume. Peter Lynch 101. Precision Engineering sounds high-tech and high-margin. Metals sounds like a commodity shed in Gujarat.

Chapter 2: The IPO

IPO opens September 4, closes September 6, lists September 11, 2023. Subscribed 94 times. Listed at 37% premium.

Here is what actually happened that day.

• Fresh shares issued to public: 1.38 crore shares at Rs 98. Company received Rs 135 crore. This money went into the company.
• Offer for Sale by promoter: 30.40 lakh of the promoter’s own personal shares sold at Rs 98. Rs 29.79 crore went directly into the promoter’s personal bank account. Not the company’s account. His account.

Retail investors handed the promoter nearly Rs 30 crore on day one for shares he already owned.

• Promoter holding before IPO: 86.3%
• Promoter holding after IPO: 55.48%

He sold 30 percent of the company to the public and pocketed Rs 30 crore personally on listing day.

Chapter 3: After Listing

This is where most people stop watching. They should not.

• Preferential allotment FY24: 45.50 lakh shares issued at Rs 134. Share count goes from 4.84 crore to 5.32 crore.
• QIP December 2025: 1.27 crore shares issued to institutions at Rs 145. Share count goes to 6.60 crore.
• Warrant conversion 12 December 2025: promoter gets 20.27 lakh shares at Rs 133. Market price that day: Rs 159. Discount per share: Rs 26. Value transferred from public shareholders to the promoter: Rs 5.27 crore. Recorded nowhere on the P&L.
• CCPS conversion March 2026: promoter gets another 1.24 lakh shares at Rs 148.27 via a preference share instrument he had issued to himself.

Share count now: 6.82 crore.

Before the IPO it was 3.47 crore. Your ownership of this company has been cut almost in half without you selling a single share.

Chapter 4: The Warrant

A warrant is a pre-locked coupon. It says I can buy shares at Rs 133 anytime in the next 18 months. The price is fixed when the coupon is issued. If the stock rises between then and exercise day, the warrant holder pockets the difference.

Look at what happened in the same week of December 2025.

• Institutions paid Rs 145 via QIP.
• Promoter paid Rs 133 via warrant.
• Retail paid Rs 159 on the open market.

Three prices in the Same week.This is how the incentive structure of this company actually works.

Chapter 5: The “Buying With His Own Money” Defence

The argument goes: he is buying shares with his own money so he must believe in the company.

He is not buying at market price. He is collecting a pre-locked discount.

Exercising a warrant at Rs 133 when the stock is at Rs 159 is not conviction. It is collecting a coupon that was already in the money. Anyone with that coupon would exercise it.

A promoter with genuine conviction walks into the open market and pays Rs 159 like every retail investor. He did not do that.

The 6% open market buying before the rights issue also has a simpler explanation. Higher holding on the rights issue record date means bigger entitlement to discounted rights issue shares. It is position management before a discount capture, not belief in the business.

And the promoter is already making money through the dilution itself. Not through selling. Through the structure. Every warrant conversion, every CCPS, every rights issue subscription at a discount is value captured. The share count goes up. Retail gets diluted. The promoter’s absolute share count stays roughly the same.

The promoter does not need the stock to go up to make money. The structure is already working for him. Every time retail buys the story and the stock rises, the next discount he captures gets larger. Every time a new share is issued, your ownership shrinks a little more.

Chapter 6: The Rights Issue

Rs 330 crore rights issue approved. Stock today at Rs 252. Issue price likely around Rs 180 to Rs 190.

Promoter at 45.49% holding gets roughly Rs 150 crore of entitlement at that discounted price.

Discount to today’s price is roughly Rs 63 per share on 79 lakh shares. That is Rs 49.7 crore captured by the promoter through rights issue pricing alone. Not recorded as a cost anywhere.

And here is what the money is actually for.

Rs 255 crore of the Rs 330 crore, 77%, is going to working capital. Not the CCL project. Not new capacity. Working capital.

The business cannot collect the cash it has already reported as profit. Trade receivables jumped from Rs 66 crore to Rs 175 crore in a single year, a 165% jump while revenue grew only 20%.

You are being asked to fund the gap between profits the company has booked and cash it never actually received.

You already paid for that profit through the price you paid for your shares. Now you are being asked to pay again to actually collect it.

Chapter 7: Is the Promoter Diluting Himself

No. He is not diluting himself. He is diluting you.

• Promoter holding September 2023: 55.48% of 4.84 crore shares = 2.685 crore shares.
• Promoter holding today: 45.49% of 6.82 crore shares = 3.102 crore shares.

His percentage appears to have fallen by 10 points. His actual share count increased by 42 lakh shares.

The percentage drop is an optical illusion created by share count expansion. Simply issuing so many new shares to everyone else that his percentage naturally dropped even as he accumulated more shares for himself at below-market prices.

Your slice of the pie was cut in half. His slice stayed roughly the same size. He grew the total pie, kept his own portion constant, and made sure every new slice he personally received came cheaper than what retail paid. That is not conviction for me .That is capital structure management in his own favour.

Chapter 8: But They Are Reinvesting. Is the Dilution Not Justified?

This will be the counter argument. Dilution is not always bad. Amazon diluted. Infosys diluted. Every great compounder raised capital at some point. So why is Ratnaveer different.

Three reasons.

First, where is the money actually going. A company that dilutes to reinvest must show the capital is going into high return productive assets. At Ratnaveer, Rs 255 crore of the Rs 330 crore rights issue, 77%, is going to working capital. Not factories. Not CCL lines. Not new capacity. Working capital. You are not diluting to build. You are diluting to fund the gap between profits reported and cash never collected. That is not reinvestment. That is plugging a hole.

Second, what is the return on capital already deployed. Every time a company asks for more capital the first question is what return did you generate on the last capital we gave you. ROCE across six years at Ratnaveer: 11%, 11%, 14%, 13%, 14%, 12%. Never above 14%. Currently falling despite significant revenue scaling. The business is generating less return on every rupee of capital as it gets bigger. That is the opposite of what reinvestment led compounding looks like.

Third, who captures the reinvestment benefit. Even if you accept that some dilution is needed for the CCL project, the structure of how that dilution happens matters enormously. When the promoter raises capital through a rights issue priced at Rs 185 against a market price of Rs 252, he captures Rs 67 of discount per share on his entire entitlement. The reinvestment may benefit the company. But the mechanism transfers value from retail to the promoter at the moment of issuance.

A promoter who is genuinely reinvesting for all shareholders raises capital at fair prices, shows improving ROCE on previously deployed capital, and demonstrates cash conversion from operations before asking for more.

None of those three conditions are met here.

Chapter 9: What the Numbers Actually Show You

This is how to think about the dilution mental model and what it does to your returns.

Look at the quarterly data first.

• Sales have moved from Rs 118 crore to Rs 315 crore over three years. Nearly tripled.
• Profits have moved from Rs 8 crore to Rs 18 crore. Around 1.5x.
• EPS was Rs 2.37 three years ago. Today it is Rs 2.55. Barely moved.

Revenue tripled. EPS went nowhere. That gap is dilution doing its work quietly in the background.

Now take the longer view from Mar 2020.

• EPS was Rs 17.70 in Mar 2020. Today it is around Rs 10.
• Sales have gone roughly 4x.
• Profits have gone roughly 10x.

Every influencer and every bull is screaming about those numbers. And they are real. But the EPS has gone backwards because so many shares have been issued over these years that your per share earnings actually fell even as the business grew.

Now look at the shareholding pattern. This is where it gets really interesting.

• FII holding two years back: 10.45%. Today: 3.53%. Absolute shares fell from 50.7 lakh to 24.1 lakh. They sold and walked out.
• DII holding: also decreasing quarter by quarter.
• Public retail holding: went from 34.05% to 48.98%. Absolute shares went from 1.648 crore to 3.34 crore.

In a genuinely high quality company the public holding keeps decreasing because institutions keep buying. Smart money accumulates. Retail gets crowded out slowly.

Here you are seeing the exact opposite. Institutions are leaving. DIIs are leaving. Retail is filling the gap that smart money is quietly vacating.

And here is the most striking number in this entire story.

Before the IPO, the entire company was 3.47 crore shares. Every asset. Every machine. Every future rupee of earnings. 3.47 crore shares was 100% of Ratnaveer.

Today retail alone holds 3.34 crore shares.

Retail has accumulated a share count almost equal to what once represented the entire company. And in return owns less than half of it.

Retail paid for the equivalent of the whole pre-IPO company. And received less than half of it in return.

That is what dilution does. You keep buying. Your share count grows. You feel like you are building a position. But the pie is expanding faster than you can accumulate. And your actual claim on the business keeps shrinking.

Chapter 10: Cash vs FCF

The P&L will never tell you this. The cash flow statement will, if you know where to look.

The company reported operating profit of Rs 115 crore in FY26. Cash from operating activity was negative Rs 48 crore.

That is a Rs 163 crore gap between what the P&L claims and what the bank account shows.

Free cash flow across every single year of available data:

• Mar 2020: negative Rs 3 crore
• Mar 2021: positive Rs 1 crore
• Mar 2022: negative Rs 28 crore
• Mar 2023: negative Rs 18 crore
• Mar 2024: negative Rs 54 crore
• Mar 2025: negative Rs 43 crore
• Mar 2026: negative Rs 155 crore

Seven years. Six negative. The one positive year was Rs 1 crore.

This business has never in its recorded history generated meaningful free cash flow. Not once.

The profits exist. The cash does not. Those are two very different things.

Trade receivables tell the same story.

• Mar 2020: Rs 64 crore
• Mar 2021: Rs 33 crore
• Mar 2022: Rs 40 crore
• Mar 2023: Rs 63 crore
• Mar 2024: Rs 45 crore
• Mar 2025: Rs 66 crore
• Mar 2026: Rs 175 crore

For five consecutive years receivables stayed in a stable range while the business grew. Then in FY26 receivables nearly tripled to Rs 175 crore in a single year while revenue grew only 20%. Debtor days doubled from 27 to 60.

This is where the reported profits are sitting. Not in the bank. In invoices raised but not paid.

Borrowings have gone from Rs 140 crore in Mar 2020 to Rs 335 crore in Mar 2026. After raising hundreds of crores through IPO, QIP, preferential allotments, and warrants, the company still carries more debt than it did before any of those raises happened.

The equity raises did not reduce debt. They funded working capital while debt stayed elevated and kept growing.

• ROCE across six years: 11%, 11%, 14%, 13%, 14%, 12%. Never above 14%. Currently falling despite significant revenue scaling.
• OPM has ranged between 8% and 12% for three straight years with no expansion despite revenue nearly tripling.

A business that triples revenue and cannot expand its margin by even one percentage point is not compounding. It is running on a treadmill and calling it a marathon.

Chapter 11: The UAE Subsidiary

My original post said the UAE LLC was incorporated 36 days before the IPO. That was wrong. It was 36 days after listing. That is my error and I own it.

But correcting the timing does not close the question.

• October 2023: subsidiary incorporated in Sharjah free trade zone.
• FY24: zero revenue, zero profit, not yet operational.
• FY25: same. Still not operational.
• February 2026, 28 months after incorporation: Rs 23 lakh transferred in as token capital. First and only financial transaction.
• Q1 FY27, June 2026, nearly three years in: zero revenue, zero profit, confirmed by the auditor.

Three years. One transaction. Rs 23 lakh. In a free trade zone built for speed. From a company that exports to 31 countries.

If anyone can explain what this entity actually exists for, I am listening.

So every year this business reports profit. Every year that profit fails to convert into cash. Every year the cash gap is plugged by raising equity or borrowing.

Each equity raise dilutes retail. Each borrowing raises interest costs, which are now at Rs 20 to 24 crore annually and growing.

The receivables line absorbs more cash each year as the company books sales it cannot collect. The ROCE is declining as capital intensity rises. And the OPM has not budged despite a tripling in revenue.

The CCL project requires Rs 472 crore of capex. The rights issue raises Rs 330 crore, of which Rs 255 crore goes to working capital. So even after the rights issue, the CCL capex is still largely unfunded. More equity raises will follow. More dilution will follow.

The numbers across seven years of data do not show a business building toward a breakout. They show a business that has always consumed more cash than it generates, funded the gap through capital markets, and used each funding round as an opportunity for the promoter to capture value at below-market prices.

And before anyone comes to argue: ask yourself one question first. After reading all of this, can you put 5 or 10 percent of your net worth into this company right now? If the answer is yes, come argue. If the answer is no, please do not waste your energy or mine debating this further.

For me, cockroaches in the account books are just the visible sign. What they tell me is the capital allocator behind them is not running this for you. I do not buy the story being written and sold. I look at where the cash actually goes, who captures the discount, and whether the person running the company is building for everyone or extracting for himself. That is my lens and I am comfortable with it.

The stock can go wherever it wants in the short term. Stories seduce. Narratives move prices. But business reality is slower and more honest than markets. A business that cannot convert profits into cash, that funds its own working capital by diluting the people who trusted it, and that has never generated meaningful free cash flow in seven years of recorded history will eventually be priced for what it is, not for what it claims to be becoming.

I stay away from models where the promoter’s incentives and the shareholders’ incentives are running in opposite directions. That is not a debate. That is a filter.

Hey guys,

Been lurking here a while and have been inspired heavily by a lot of your posts, most of all superbpercentage8050. His mental models genuinely changed how I invest, and I wanted to share what I've been up to.

Over the last 6 months I applied those frameworks to my US and India stocks. Nothing flashy, just small, disciplined wins, but they've beaten the indexes so far (numbers and proof in the slides). Ofc there are slight variations basis my judgement calls as well but the framework is a core part of the process.

I also used the same models to build a framework with Claude that screens opportunities for me every week. Each stock runs through a "gate" first, then pre-set price tiers decide the buy. I've attached two examples: one it said accumulate (RDDT) and one it said avoid (Galaxy Surfactants), so you can see the logic both ways - both are basis EOD Friday's data.

PS: the goal was never a 100% moonshot on some trade. It's to stay disciplined and beat the indexes by 7-10% over a long horizon. Optimistic, I know, but I'll take it if it holds.

Happy to answer anything in the comments 😊

The Winner's Curse

In a competitive bidding environment, the winner is often the one who made the biggest mistake in calculating their costs.

Winning a contract at 4% margin when your cost of capital is 12% is not a win. It is a contractual obligation to lose money. And the business model has just won a liability.

This is why order books seduce retail investors and destroy their capital at the same time because a bulging order book feels like visibility, like safety, like growth. But an order book is only as good as the economics embedded in each contract.

If the margin is sub-cost-of-capital, the order book is not a pipeline of value creation but a pipeline of destruction, locked in and contractually guaranteed. The bigger it gets, the faster capital is destroyed.

So alway remember size without pricing power is not an asset. It is a commitment to underperform.

In case you missed it: The AI Bottleneck Strategy, Where the Real Opportunities Are

Now before you apply this model, one important distinction.

There are three kinds of low margin businesses. Most investors cannot tell them apart. After reading this, every reader of this community will see what 99% of the market completely misses.

Type 1 is structurally thin. The business earns low margins because the industry has no pricing power, competition is intense, and there is no reinvestment opportunity that changes the economics. Margin is thin because the business model is thin. This is where the Winner's Curse fully applies.

Type 2 is turnover-driven. The business earns low margins but high asset turnover generates strong ROCE. Dixon turning its asset base 4 to 5 times a year converts a 4% margin into 20% ROCE, well above cost of capital. Kalyan operates similarly in jewellery. The margin looks thin but the capital efficiency is real. The risk in Type 2 is that the ROCE is borrowed from the customer's goodwill. The moment a large customer reprices or pulls the contract, both margin and turnover compress simultaneously and the ROCE collapses. The customer owns the economics, not the supplier. Respect Type 2 businesses but always ask whether the ROCE is structural or fragile.

Type 3 is reinvestment-suppressed. The business has strong underlying unit economics but is deliberately choosing to report thin margins because every rupee of potential profit is being ploughed back into building the next layer of the moat. Amazon and Eternals are the clearest examples. The margin is not structurally thin. It is optionally thin. The moment reinvestment slows, margins surface and they are high. AWS alone runs at 35%+ operating margins. The reinvestment was optionality, not necessity.

The way to distinguish Type 3 from Type 1 is one question. If the business stopped reinvesting tomorrow, what would the margin look like? For a Type 3 business the answer is very high. For a Type 1 business the answer is exactly the same or worse. There is no hidden margin waiting to surface. The thin margin is the business.

You want to own Type 3 businesses at the reinvestment stage if you can identify them early. Type 1 businesses at any stage are the Winner's Curse in its purest form. Type 2 businesses sit in between, real but fragile.

The full test is always ROCE versus cost of capital, then defensibility of that ROCE across cycles. Not margin in isolation.

Someone asked me what cost of capital actually means. Here is the simplest way I know to explain it.

Imagine you take a personal loan at 15% to invest in the market. Your cost of capital is 15%. Now if your investment returns 25%, you are creating value. Net return is 10%. That is the trade working.

But here is what actually happened to a lot of people in 2023 and 2024. They borrowed at 15% and bought gold, silver, or equities at the peak of the narrative. Their holdings are now making 2 to 3%. Cost of capital is 15, returns are 3, net outcome is minus 12. That is not investing. That is capital destruction on an EMI schedule. And because the EMI arrives every month regardless of what the market does, the pressure compounds before the losses even show up in your portfolio holdings.

Now flip it. Imagine you are in Japan where personal loan rates are under 1%. You invest in a dividend-paying asset returning 8% with no capital growth at all. Cost of capital is 1, return is 8, net outcome is 7%. Same asset. Completely different economic reality.

This is exactly what Buffett did with the five Japanese trading houses. He borrowed in yen at roughly 0.5%, invested in companies paying 3 to 4% dividends, and waited. The interest rate gap alone was value creation before any price movement. When the market eventually corrected the mispricing, the stocks appreciated 15 to 20% on top of the dividend yield. The total return compounded to 22 to 23% net of borrowing costs. But that appreciation was not the base case. It was the bonus. The base case was the interest rate gap. The discipline was borrowing in the same currency as the investment so there was no currency mismatch eating into the return.

That is what cost of capital arbitrage looks like when it is executed with patience and precision. Not borrowed money chasing momentum. Cheap capital deployed into undervalued, cash-generating assets and held long enough for the market to recognise what was always there.

That is why cost of capital is not a fixed number. It is personal, it is contextual, and it determines whether a seemingly identical investment creates or destroys wealth depending entirely on what you paid to access the capital.

At the company level the logic is identical but the number looks different across geographies. In Japan the cost of capital for most businesses sits between 4 and 6% because rates have been near zero for decades.

In the US it sits between 7 and 8% because the risk free rate alone is around 4.2 to 4.5%.

In India the benchmark for most businesses is 10 to 12% because the 10 year government bond sits around 7% and the emerging market risk premium adds on top of that.

This is why a business earning 8% ROCE means three completely different things depending on where it operates. In Japan it is creating value. In the US it is barely breaking even. In India it is destroying wealth. Same return. Three different economic realities. The hurdle is everything.

At the company level the hurdle is called WACC, weighted average cost of capital. It is the blended cost of every rupee the business uses, what it pays on debt and what return its equity shareholders expect for the risk they are taking. If a business cannot earn above that hurdle on the capital it deploys, it is destroying wealth even if the reported profit looks positive. The profit is real. The value creation is not.

So how do you use all of this in practice.

First seek out businesses where margins are already high relative to cost of capital. That is the cleanest signal of a right pool.

When you find a low margin business that is still compounding, do not dismiss it and do not blindly buy it either. Ask which type it is. Type 1, Type 2, or Type 3. That question alone will save you more capital than any screener ever will.

And if you are ever comparing a high margin business with a long reinvestment runway against a low margin business at the same market cap and the same multiple, do not make it complicated. The high margin model with reinvestment runway wins every time.

You are getting more durable compounding for the same price. That is not a close call.

One more thing before you go.

If you have identified the right type of business and the order book economics are sound, timing still matters. Buy when the sector tailwinds are just beginning and the order book has not yet exploded. At that stage the market has not priced in the growth and you are buying visibility before it becomes consensus.

Do not buy after the order book has already exploded and the re-rating has happened. By then the growth is in the price. The easy money has been made by someone who saw it earlier.

And when you are analysing the order book itself, ask one more question. How much of it generates recurring revenue versus one-time execution? Some businesses have thin margins on the base contract but high margins on the service, maintenance, and upgrade layer that follows. If the service revenue share is growing inside the order book, margins will improve on a blended basis over time. That is a genuine quality signal. If management is talking up the order book but the service mix is not improving, they are marketing the size, not the economics. Watch the blended margin trend, not the headline order book number.

This is one of 7 mental models from the trap detection framework I published here. Breaking each one out so we can go deeper together.

Now let us brainstorm. Drop in the comments:

• A stock where you experienced this illusion firsthand and the order book looked like a thesis but the economics did not hold
• Did you position before the order book was marketed to you as the thesis, or after it had already exploded into the narrative
• And if you have seen a Type 1, Type 2, or Type 3 business play out in your own portfolio, share it. That is where the real learning is.

Further Reading:

•  7 mental models every investor should run before buying any stock
• Part 2: The One Ratio That Tells You When to Buy Gold and When to Go Aggressive on Stocks

Many of you have joined this community in the last few months. This one is for you.

Seven months ago I published a trap detection framework here using UDS as the stress test. The original post sparked one of the longer discussions this community has had on business model quality.

Since then the audited FY26 results and Q1 FY27 filings have come in, and every single warning played out exactly as described. I have now rebuilt the piece with the real numbers embedded after each mental model.

Before you scroll, one thing worth knowing. This is a long piece. You do not have to read it in one sitting. Every mental model is complete in itself. Read one, close the tab, go run it on a stock you own. Come back for the next one tomorrow.

But if you do read it end to end, something interesting happens. The models start connecting. Each one reinforces the next. By the time you reach the seventh, you are not just holding seven tools. You are holding one integrated lens that lets you see the whole picture at once.

I call it the latticework effect. I will let you experience it for yourself.

Important note to readers: This isn't a post about a single company. UDS is only the case study, serving as the stress test used to understand how certain business models quietly destroy value. Every mental model here can be run on any stock you are holding right now — not just UDS. That is the whole point.

Let us get into it.

Most retail investors lose money not because they pick bad stocks, but because they fail to recognize Bad Business Physics until it's too late. By then, the "clean numbers" they relied on through screeners have already evaporated. Inside, we're going to break down 7 mental models that act as early-warning systems for value destruction:

1. The Janitor Economy: Why essential work rarely earns a premium.
2. The Red Queen's Race: Why some companies run faster just to stay in the same place.
3. The Winner's Curse: Why winning the contract is often the beginning of the end.
4. The Hamster Wheel: Why motion is so often confused with wealth.
5. The Oxygen Test: The brutal reality of cash vs. growth.
6. The Cockroach Theory: Why there's never just "one" minor accounting issue.
7. The Toxic Pond: Why even a great CEO can't swim in a graveyard.

Business Model Quality

Before looking at numbers, it is important to understand the basic nature of the business model.

Think of a large hospital or a global IT campus like Microsoft or Amazon. These companies are excellent at healthcare or software, but they do not want the operational headache of managing thousands of janitors, security guards, and back-office staff, or the legal risk that comes with payroll and labour compliance. So they outsource this mess to UDS.

At its core, UDS is a labour-management platform. The business runs on human capital arbitrage. It appears asset light because it owns no factories, but in reality it is labour heavy and working-capital intensive, with weak margins and limited pricing power.

Mental Model 1: The Janitor Economy

Janitors are essential to any operation, but they are never paid premium wages or given premium respect. The same economic logic applies to businesses that perform "messy" but commoditized work. These business models are essential but they are never paid a premium by their clients or a premium multiple by the market.

Train yourself to notice this pattern: when a customer pays you to clean up a headache rather than create a unique value, they will always treat you as a cost center, not a partner. Businesses that operate in the "clean-up" economy rarely have the pricing power needed to survive inflation or wage hikes. They are essential to the world, but toxic to your portfolio.

What actually happened

• Employee costs in FY26: ₹2,294 cr on revenue of ₹2,939 cr — 78% of revenue consumed by labour alone
• A year earlier it was 74%. The direction is wrong and accelerating
• By Q1 FY27: employee costs were ₹600 cr on revenue of ₹764 cr — 78.6% of revenue
• The business did not escape the Janitor Economy. It sank deeper into it
• These numbers are from the audited consolidated filings, not estimates

Revenue Quality

UDS operates through two segments. Integrated Facilities Management (IFM) contributes roughly 67 percent of revenue, while Business Support Services (BSS) contributes about 33 percent.

Historically, UDS reported 20-25 percent growth in the period leading up to the IPO. That growth was largely inorganic, driven by aggressive acquisitions such as Athena BPO and Denave, and was heavily marketed to retail investors to trap them.

This acquisition-led growth illusion is now over. Overall revenue growth has slowed to 7 percent, and more importantly, the quality of growth has deteriorated.

• The IFM segment grew around 10 percent, but PAT margins collapsed to just 3.4 percent. This clearly signals growth driven by volume at the expense of price.
• The company is winning new "strategic contracts" and marketing them aggressively in annual reports and concalls, but these contracts come with upfront costs and thin margins. Growth here simply means more employees and weaker economics per unit.
• The BSS segment, which management positioned as the growth and quality engine, grew by only around 2 percent, exposing weak organic demand and high sensitivity to global IT hiring cycles.

In Q2, the deterioration became more visible. Revenue increased by 7 percent, but EBITDA collapsed by 28 percent, and net profit declined by 29 percent due to margin compression. This is not operating leverage. This is scale working against the business.

Mental Model 2: The Red Queen's Race

When a business has to keep running just to stay in the same place, scale stops creating value and starts destroying it.

Train yourself to notice this pattern: when a company's capex or acquisitions only serve to match a competitor's move or artificially maintain revenue, it's not an investment, it's an expensive survival tax. If they stop running, they die. If they keep running, they stay exactly where they are, but with significantly fewer resources and a weaker balance sheet.

While UDS is a labour-management case study, the same Toxic Physics applies to the majority of infrastructure, construction, and capital-intensive companies.

What actually happened

• Revenue FY26: ₹2,939 cr — grew 7.4%
• PAT FY26: ₹82.7 cr — fell 30.4%
• EPS: dropped from ₹17.74 to ₹12.80 — a 27.8% fall in per-share value
• Workforce grew to 76,000 people
• The company ran harder, added more contracts, deployed more people, and ended the year materially poorer on a per-share basis
• More motion, less wealth — the Red Queen ran exactly as described

Margin Truth

UDS does not clear even a single layer of my 8-layer margin framework. In business physics, scale is supposed to improve operating efficiency. As businesses grow, fixed costs spread out and margins expand. UDS is showing the inversion of this rule. As scale increases, margins are collapsing. This is diseconomies of scale.

Look at the numbers:

• Q2 FY25 operating margin: 6.4%
• Q2 FY26 operating margin: 4.4%

This margin compression is not cyclical pressure. It is structural margin erosion.

Management attributes this to "upfront costs" for new strategic contracts. This explanation itself is the red flag. If a business has a moat, it does not need to buy revenue by sacrificing 200 basis points of margin. In labour-commodity businesses, "upfront costs" usually mean underbidding competitors just to win contracts.

UDS attempted to offset its weak core margins through acquisitions. Denave and Athena were acquired for their reported 10-15% margins to improve the blended profile. Instead, capital was deployed at high premiums just as IT hiring slowed.

The margin mix is now reverting back toward the low-quality 4-5% core. At this level, there is no margin of safety. A business earning 4-5% operating margins is one mistake away from trouble. A 2% wage hike or a short delay in client payments can wipe out an entire quarter's profit. With the 8th Pay Commission, this fragility is no longer a risk. It is a reality.

Mental Model 3: The Winner's Curse

In a competitive bidding environment, the "winner" is often the one who made the biggest mistake in calculating their costs.

Understand the hard truth: winning a contract at a 4% margin when your cost of capital is 12% is not a win, it is a contractual obligation to lose money. The contract looks like growth on paper, but it destroys economic value from day one. They haven't won a prize. They have won a liability.

What actually happened

From the Q1 FY27 segment filing:

• IFM segment: revenue ₹527 cr, PBT ₹21.5 cr — margin of 4.1%
• BSS segment: revenue ₹255 cr, PBT ₹13.3 cr — margin of 5.2%
• Both remain below a reasonable cost of capital
• These are the margins of a business that keeps winning contracts it cannot afford to win
• The Winner's Curse is now visible in the segment disclosures themselves

ROCE

ROCE is where all illusions finally collapse. A business can show revenue growth and even accounting profits, but if incremental capital earns sub-par returns, scale does not compound wealth. It destroys it.

UDS is a textbook case. For years, reported ROCE looked healthy. The 10-year average ROCE was above 18 percent. But the moment you look at incremental ROCE, the story changes.

• FY22 ROCE: 22.1%
• H1 FY26 ROCE: 13.0%
• TTM ROCE: 9.9%

In less than a year, the business lost nearly 40 percent of its capital efficiency.

In an economy like India, where the cost of capital is roughly 10-12 percent, an ROCE of 10 percent means the business is barely earning its cost of capital. Anything below this is value destruction, not compounding.

In labour-heavy businesses, ROCE should improve with scale if pricing power exists. At UDS, every incremental contract requires more people, higher wage advances, higher receivables, and more execution risk. There is no operating leverage here. There is only operational drag.

Mental Model 4: The Hamster Wheel

High activity and aggressive capital deployment can create a powerful illusion of progress. But if each turn of capital earns less than the cost of capital, the business is simply running hard while going nowhere. Motion increases. Wealth does not.

The diagnostic rule is simple: when a business earns a 10% ROCE in a 12% cost-of-capital world, it is not "profitable", it is a wealth destroyer. Every new contract it wins is actually making shareholders poorer. You are watching a company sprint with maximum effort just to achieve a negative return on your life savings.

What actually happened

From the audited FY26 consolidated filing:

• Capital employed grew from ₹964 cr in FY25 to ₹1,055 cr in FY26
• EBIT on that capital: ₹101 cr
• Implied ROCE: approximately 9.6%
• More capital deployed, lower return earned per rupee
• Every incremental rupee of capital destroyed value in FY26
• The wheel kept spinning. Shareholders got poorer.

Cash Flow

Every retail investor should always remember this rule: earnings are an opinion. Cash is a fact.

This is why investors like Charlie Munger and Terry Smith have always preferred cash-generating machines. Real compounders don't just report profits. They convert profits into cash. This is the ultimate test of any high-quality compounding business.

UDS fails this test.

High-quality businesses typically convert 70-80 percent of their profits into operating cash flows. UDS's cash conversion has been consistently below 30-40 percent and highly volatile. That alone disqualifies it as a compounding engine.

Management explains this away using phrases like "strategic ramp-ups." That is just marketing language. In reality, it means cash is being spent upfront to sustain reported growth.

The structural reason is simple. UDS pays its employees every month in hard cash, while its clients sit on payments for 60, 90, sometimes 120 days. As scale increases, this mismatch explodes. Trade receivables stay stuck at 30-35 percent of total assets. Profits look alive on paper, but the cash never reaches the bank and never reaches shareholders.

Mental Model 5: The Oxygen Test

Cash flow is the oxygen of the business. It determines longevity.

Never lose sight of the fact that when growth consumes cash instead of generating it, shareholders are funding the business, not the other way around. Real compounders breathe out cash. Value traps suck it in. If a business needs a constant infusion of fresh capital to sustain its reported growth, you are not an investor. You are a donor.

What actually happened

This is the one number that looks better on the surface, so it deserves the most careful reading.

• Operating cash flow improved from ₹50.8 cr in FY25 to ₹143.6 cr in FY26
• Bulls will point to this as evidence of recovery

Here is what the actual cash flow statement shows:

• Trade receivables grew by ₹46.3 cr in FY26 versus ₹120.1 cr in FY25
• The working capital drag reduced not because the business got better at collecting cash, but because growth slowed
• When you grow slower, you consume less cash upfront
• Cash improved because the business decelerated, not because its underlying physics changed

That is not recovery. That is slowdown dressed as improvement.

Balance Sheet Illusion

On your screeners, UDS will appear low-debt and financially conservative, signalling a clean balance sheet. This is, again, an illusion.

The cash sitting on the balance sheet is not earned. It came from the IPO. That is retail investors' money, not business-generated cash. And even that cash was misallocated.

A large part of the IPO proceeds was deployed into acquisitions, mainly inside the BSS segment, which management sold as the "quality" and "growth" engine. That bet has failed. Growth rates have faded. Margins have compressed. The very segment that was supposed to upgrade the business has instead destroyed shareholder value. In simple terms, retail capital was used to buy low-quality growth at high premiums.

The bigger problem is that a meaningful portion of reported profits does not come from operations at all. Roughly 25-30 percent of net profit is supported by other income, primarily interest earned on IPO proceeds parked in bank deposits. In other words, part of the profitability is coming from doing FDs with retail capital, not from running a high-quality business.

The risk does not stop at poor capital allocation. One subsidiary, Avon, has already reported financial irregularities. Apply the Cockroach Mental Model here.

Strip away IPO cash, failed acquisitions, and FD income, and the "clean" balance sheet collapses into a fragile one.

Mental Model 6: The Cockroach Theory

If you see one cockroach in your kitchen, you don't assume there is only one. You assume there are hundreds hiding behind the walls.

The forensic rule: when a company shows even one small accounting irregularity or a minor provision in a subsidiary, it is never an isolated incident. In professional investing, there is no such thing as an honest mistake in only one corner of the balance sheet. One crack in the reporting usually means the entire foundation is rotting. If management is willing to adjust the small numbers, they have already lost the map on the big ones.

What actually happened

This one deserves to be read slowly. Note 8 of the audited FY26 consolidated filing states that an external independent expert investigated allegations of irregularities involving sales transactions with certain customers and vendors in Avon.

• Original disclosure: a small provision of ~₹3 cr, ₹25 cr of receivables under scrutiny
• Final recorded provision: ₹23.1 cr — roughly 7.7 times larger than the initial framing
• The entire logistics business inside Avon was shut down completely
• The investigation was commissioned by the company itself
• Management concluded no further impairment was necessary beyond what was already recorded

Three things to hold in your mind. A cockroach that was initially described as ₹3 cr turned into ₹23.1 cr and killed an entire business vertical. The investigation that cleared it was not independent in the true sense. And the gap between initial disclosure and final reality is the Cockroach Theory confirmed in the company's own audited filing.

Reverse Engineering the End State

I always tell retail investors to reverse engineer the ecosystem gorilla or global peers before believing the story. It acts like a time machine and removes hope from the analysis.

To understand where UDS's business model actually leads, reverse engineer Quess Corp. It represents the scaled, mature end state of this labour-management ecosystem.

• Quess Corp expanded revenue from roughly ₹3,435 cr in FY16 to about ₹15,159 cr — a nearly 5x increase in scale
• Despite this growth, EPS declined by roughly 50 percent over the same period
• Margins compressed from the 4-5 percent range to nearly 2 percent
• Since its IPO in 2016, Quess Corp's stock is down 57 percent, despite operating at far greater scale, with brand strength and industry leadership

When the ecosystem gorilla cannot convert scale into shareholder wealth, the odds for smaller players are not better. They are worse. The problem is not execution. The problem is the business model itself.

Mental Model 7: The Toxic Pond

If the biggest, strongest fish in the pond is starving to death, you shouldn't expect the smaller fish to thrive.

The strategic filter: when the sector leader has failing margins and a decade of zero stock returns, the problem is the sector physics, not the management. No amount of efficient execution can save a business from a toxic industry structure. When the industry's fundamental economics are broken, even the best CEO is just a captain on a sinking ship. Don't go looking for gems in a graveyard.

What actually happened

• Quess Corp continues to operate at sub-2% net margins at scale
• UDS closed FY26 at a 2.8% consolidated net margin
• UDS is not outperforming the gorilla in any meaningful way
• The stock moved from a 52-week high of ₹420 to ₹172 on results day
• Investors who relied on screeners and the IPO narrative have lost more than half their capital in under two years of listing
• The pond did not get cleaner. The fish did not get stronger.

One honest green shoot

BSS grew 7.3% in Q1 FY27 after being essentially flat all of FY26. Management is pivoting the BSS narrative around AI, repositioning Denave as an AI-enabled demand generation platform.

This deserves watching, not dismissing. If BSS margins hold above 5% and revenue growth sustains above 7% for two more consecutive quarters, the narrative deserves a closer look. Watch the segment disclosures in the next two quarters, not the concall language.

One quarter does not change the pond. But it is the one number worth tracking.

Final thoughts

This case study is not about being right on one stock. It is about learning how value destruction actually happens in the real world. Traps rarely announce themselves through losses. They hide behind growth, acquisitions, low valuations, and reassuring screeners. By the time numbers break, capital is already gone.

The seven mental models in this piece have now been tested against real audited data across seven months. Every single one held. The Janitor Economy, the Red Queen, the Winner's Curse, the Hamster Wheel, the Oxygen Test, the Cockroach Theory, the Toxic Pond — all confirmed, in the company's own filings, without exception.

Take these lenses and run them on your own portfolio holdings. Run them on the next idea a financial influencer throws at you. Ask whether the business deserves capital before you ask whether the stock is cheap.

Your money is hard earned. Protect it first. Compound it second. And never mistake motion for wealth.

The goal is not to predict outcomes. The goal is to avoid toxic ponds altogether.

For people new to this subreddit, this post is about the lens, not the stock. Stocks are a byproduct. The mental model is what matters. Once you internalise Capillary economics, it starts firing on its own across sectors, across cycles, across everything you look at.

If you are new here and want to understand what Capillary economics actually is before reading further, start with the:  Capillary Economics mental model 

Here is what I had written a few months back. Read it for the thinking, not the ticker.

A boring 7,000 crore company with a 3x setup hiding in plain sight.

On the screen this looks like a declining business. But almost every engine is now sitting on the right side of the opportunity-cost mental model, the roots have strengthened, and what's coming is structurally better than what the ticker shows, with a high margin of safety while you wait.

That's why I had already started allocating to Galaxy Surfactants.

This is Capillary economics for you again. Galaxy doesn't own a brand you'd recognise on a shelf, but it sits inside the supply chain of nearly every brand you do. So they make surfactants, which are a small cost in home and personal care, so whether the bottle says HUL, P&G, Unilever, L'Oréal, Mamaearth or some small D2C startup, Galaxy is somewhere in that formulation.

So it's a low cost, high necessity model, which is cheap enough that customers don't fight it, but critical enough that they can't drop it. It doesn't earn toll-booth margins today, and the numbers are still depressed, but it holds the kind of position that can become a toll booth once the mix shifts and the margins follow. That's the whole bet.

And here's the bigger picture. India is at that stage of the adoption curve where China was 10 to 15 years back, and the US was 40 years back. As per-capita income rises, you'll see massive adoption of liquid detergents and higher spend on personal care, and Galaxy sits underneath all of it as an invisible cost, very small but absolutely critical. That's exactly the kind of business I want to own when it's cheap and out of favour.

Always use this Capillary mental model. Whenever you see this pattern with high necessity and low cost in any company, you know it has the DNA to become a toll booth, and try to find companies which are small but have massive room for margin expansion and have the positioning inside their ecosystem to make that happen. That's where real money gets made.

Businesses of this shape usually trade at 2.5 to 3x revenue over a full cycle. Galaxy was doing roughly 5,000 crore of revenue. The valuation should sit near 12,000 to 15,000 crore of market cap, versus the 7,000 crore where it was trading.

That's the gap. Your job is to think why the gap is there and whether it closes.

Here is how the future state emerges. First comes the expansion of the margin profile, because the reasons the margins are depressed are temporary, not structural. Roughly 20% of the cost base is crude-linked, and crude-linked costs were high because of freight and raw material pressures, a cycle and a war phenomenon, not a permanent feature.

Second, their major input is fatty alcohol, made from palm kernel oil, and PKO ran hot for a few years. But the decline in input cost was already visible, management had flagged that raw material prices were starting to ease, and the 2025 price pressure was unwinding into 2026 as supply and demand rebalanced.

On top of that, they have a clause that lets them pass costs on to customers within 60 to 90 days, and a deliberate shift towards higher-margin products that was steadily changing the mix.

So here is the chain. Once the headwinds fade, margins expand. When margins expand on a rising revenue base, you get massive EPS expansion. And that EPS expansion is what triggers the PE multiple re-rating on top of it.

Let me give you two examples of this exact pattern.

Shivalik Bimetal had the same positioning. A decade back margins were around 11%, they steadily shifted to 23%, the market re-rated them, and now they trade at 30 to 40 multiples.

Same story with Navin Fluorine. A margin profile of around 12 to 13%, then they started shifting it, and now with the tailwinds in confluence the market cap is close to 40,000 crore on revenue of 3,314 crore, trading at 11 to 12x revenue.

Coming back to Galaxy. Even with just a 6 to 7% growth rate over the next 5 years, revenue comes close to 7,000 crore. Give that a 3x revenue multiple and the market cap reaches 21,000 crore, almost a 3x outcome. At only 2x revenue, it's still a double in 5 years, with a decent margin of safety.

The ticker caught up today. The business state was always there.

That's Capillary economics. Take the lens. The stocks will follow.

The community went deeper on the business state vs ticker state thinking in the comments here, worth reading if you want to see the framework applied in real time.

https://www.reddit.com/r/IndiaGrowthStocks/comments/1uf08tv/comment/p3i1pin/

Inspired by William Green’s book Richer, Wiser, Happier and the investment principles of exceptional long-term stock pickers including Nick Sleep, Warren Buffett, Charlie Munger, Sir John Templeton and Mohnish Pabrai.

USE CASE
ㅤ
Most stock screens tell you P/E, profit growth, ROIC and free cash flow.
ㅤ
But they don’t answer the harder questions:
ㅤ
Is the cash flow real?
Is ROIC sustainable?
Can the company keep reinvesting at high returns?
Does it actually have a moat?
Can management be trusted?
Is all the future growth already priced in?
Is there a better stock available for the same capital?
ㅤ
So I built NAIL 2.0.
ㅤ
The goal is to find businesses where growth, ROIC, cash generation, competitive advantage, management quality and valuation combine to create exceptional long-term risk-reward.
ㅤ
For broad searches using pro AI models such as “Find the best stocks in India”, first screen the market, shortlist around 15-20 candidates, deep-dive only the strongest finalists and rank the best 3-5.
ㅤ
NAIL 2.0
ㅤ
N = NUMBERS AND CASH QUALITY
ㅤ
30 POINTS
ㅤ
Check 3Y and 5Y sales, EBITDA, PAT and EPS growth.
ㅤ
Separate organic and volume growth from price-led or acquisition-led growth.
ㅤ
Check current and 5Y ROIC, incremental ROIC on new capital deployed, 5Y cumulative CFO/PAT, 3Y and 5Y FCF, FCF per share and normalized FCF yield.
ㅤ
Also check receivable days, inventory days, payable days, cash-conversion cycle, net debt, interest coverage and contingent liabilities.
ㅤ
Most important question:
ㅤ
Is FCF structurally sustainable, or temporarily boosted by working-capital release, unusually low capex or one-offs?
ㅤ
Score: /30
ㅤ
A = ADVANTAGE AND GROWTH RUNWAY
ㅤ
25 POINTS
ㅤ
Check the business model, industry growth, addressable market, market-share trajectory, pricing power and customer stickiness.
ㅤ
Identify genuine advantages from brand, technology, distribution, cost, scale, qualifications or switching costs.
ㅤ
Check customer concentration, supplier concentration, cyclicality, disruption risk and capacity expansion.
ㅤ
Most importantly, determine whether the company can reinvest substantial capital for many years at high ROIC.
ㅤ
Answer:
ㅤ
Why can this company become substantially larger in 5-10 years?
ㅤ
Classify the moat as Strengthening, Stable, Weakening or None.
ㅤ
Score: /25
ㅤ
I = INTEGRITY AND CAPITAL ALLOCATION
ㅤ
20 POINTS
ㅤ
Check promoter holding, promoter pledging, auditor changes or qualifications, related-party transactions, warrants, preferential allotments and dilution.
ㅤ
Check management remuneration, guidance versus actual delivery, acquisitions, unrelated diversification and treatment of minority shareholders.
ㅤ
Then answer:
ㅤ
What has management done with every Rs 100 of cash generated?
ㅤ
Did it go toward high-ROIC capex, sensible acquisitions, debt reduction, dividends or buybacks?
ㅤ
Or was shareholder value destroyed?
ㅤ
Score: /20
ㅤ
L = LONG-TERM VALUE AND ASYMMETRY
ㅤ
25 POINTS
ㅤ
Check current versus historical valuation, peer valuation, P/E, EV/EBITDA, EV/FCF and FCF yield.
ㅤ
Use normalized earnings for cyclical companies.
ㅤ
Determine how much growth is already implied by today’s share price.
ㅤ
Ask why the market may be wrong.
ㅤ
Compare forecasts with realistic historical base rates.
ㅤ
Finally, compare the opportunity against better stocks available today.
ㅤ
Build realistic five-year Bear, Base and Bull cases.
ㅤ
For each scenario estimate sales/PAT, exit valuation, possible share price and expected CAGR.
ㅤ
Final question:
ㅤ
Is potential upside materially greater than permanent downside?
ㅤ
Score: /25
ㅤ
AUTOMATIC OVERRIDE
ㅤ
Regardless of numerical score, classify the stock as High Risk or Avoid if credible evidence exists of accounting manipulation, serious auditor concerns, related-party abuse, misleading disclosures, unsustainable debt, dangerous promoter pledging, persistent unexplained CFO/PAT weakness, repeated destructive dilution or structural business deterioration.
ㅤ
A numerical score cannot override an integrity problem.
ㅤ
NAIL GRADES
ㅤ
90-100 = A++ Exceptional
85-89 = A+ Elite
80-84 = A Excellent
75-79 = B+ Strong
70-74 = B Watchlist
60-69 = C Average / Special Situation
Below 60 = D Avoid
ㅤ
GREAT STOCK-PICKER PANEL
ㅤ
Keep these scores separate from the NAIL score.
ㅤ
Nick Sleep: /10
ㅤ
Destination analysis, scale economies, customer proposition and long reinvestment runway.
ㅤ
Buffett-Munger: /10
ㅤ
Durable moat, owner earnings, management integrity, predictability and purchase price.
ㅤ
Sir John Templeton: /10
ㅤ
Normalized intrinsic value, pessimism, contrarian opportunity and margin of safety.
ㅤ
Mohnish Pabrai: /10
ㅤ
Simple thesis, downside protection and asymmetric upside.
ㅤ
These scores apply their publicly known investment principles. They aren’t claims about what those investors would personally buy.
ㅤ
COPY-PASTE AI PROMPT
ㅤ
Research COMPANY / TICKER using NAIL 2.0.
ㅤ
Use the latest annual reports, quarterly results, NSE/BSE filings, investor presentations, concalls, credit-rating reports and competitor or industry data.
ㅤ
Cross-check important figures and clearly separate reported facts, management claims, estimates and interpretation.
ㅤ
Grade:
ㅤ
N - Numbers and Cash: /30
A - Advantage and Runway: /25
I - Integrity and Allocation: /20
L - Long-Term Value: /25
ㅤ
Also score:
ㅤ
Nick Sleep: /10
Buffett-Munger: /10
Templeton: /10
Pabrai: /10
ㅤ
Finish with:
ㅤ
NAIL Score: XX/100
Grade:
Current valuation:
Preferred buy valuation:
Bear / Base / Bull 5Y CAGR:
Biggest strength:
Biggest risk:
Why the market may be wrong:
Single thesis breaker:
3 numbers to monitor:
Action: Buy / Accumulate / Wait / Hold / Reduce / Avoid
ㅤ
Do not force a bullish conclusion.
ㅤ
For broad requests such as “Find the best stocks in India”, first screen broadly, shortlist 15-20 candidates, deep-dive only the strongest finalists and rank the best 3-5.
ㅤ
FINAL IDEA
ㅤ
NAIL 2.0 isn’t trying to find the stock with the lowest P/E.
ㅤ
It is trying to find the combination of:
ㅤ
High ROIC
Strong cash conversion
Long reinvestment runway
Durable competitive advantage
Good management
Reasonable valuation
Asymmetric upside versus permanent downside
ㅤ
What would you add, remove or change?

Someone in the community asked me a very simple question: what style of investing do you follow? Bottom up or top down?

I sat with it for a moment. And my honest answer was this: randomness.

Not in the decisions I make, but in how I find what to research.

Sometimes it's a line in management commentary that catches me off guard and makes me want to understand the business better. Sometimes it's the capital allocation pattern of a company's competitor, not the company I was originally looking at. Sometimes it's a government report pointing to a tailwind I hadn't mapped to any business yet. Sometimes it's a margin shift, a changing business state, or a new technology quietly reshaping an industry.

I make sure not to follow any particular pattern when I enter research. The trigger can come from anywhere.

A lot of investors define their sphere of competence by sector. They stay in what they know, follow a formula, and only look inside that boundary. I understand the logic. But for me, the sphere of competence is curiosity itself.

That curiosity can start anywhere. A web series like Person of Interest led me to go deep into AI, semiconductors, and cybersecurity. A government scheme on BharatNet led me to the fibre rollout theme in India. And the same curiosity that pulls me into a business also tells me when to leave. The moment I see the first signature of a deteriorating business model, I start moving out. I don't wait for consensus to confirm what the signals are already saying.

What stays constant is the rigor after the trigger. Once something catches my attention, I run it through the full checklist. I stress test the business model, look at the financial signature across multiple years, align the thesis with as many mental models as I can, and only then decide if there's something worth owning.

The randomness is in the door I walk through. What happens inside is deliberate.

Let me give you a concrete example. I recently initiated a position in Unity Software.

The trigger was XR. Meta Quest, smart glasses, the gradual convergence of human and machine interfaces. I had no idea what Unity did at first, but I knew that wherever this technology goes, someone builds the infrastructure underneath it. That question led me to Unity: what lies in the future, where is the infrastructure of that ecosystem, and who dominates it.

Then I went layer by layer.

Unity dominates roughly 70% of the gaming ecosystem. But that same technology is now being used in automotive HMI, inside autonomous and semi-autonomous vehicles. They are in partnership with Mercedes. That same technology is being adopted in China, and Unity provides it there too. These are early stages, but the reinvestment runway is real. A dominant core business model with a strong allocator redirecting that technology into new age applications is exactly the kind of setup I look for.

This is how curiosity compounds. You start with one signal and keep pulling the thread.

But curiosity alone is not enough. Once I have a thesis, I run it through the checklist. Is the ROIC improving? Is it above my threshold? Are margins expanding? Is innovation continuing? Are they taking market share? You keep hitting the mental models until you have a probability, not a certainty, but a probability. If the position clears the threshold, you start building it slowly.

The business had deteriorated badly before this. Extreme compression, reckless acquisitions, a company that had lost its way. But something changed in 2024. A new capital allocator came in.

I am not reading the marketing language of a CEO. I am reading the financial actions.

What did he acquire and what did he let go. What did he stop doing. What did he quietly fix. This one was slowly and steadily unwinding every reckless decision his predecessor had made, refining the focus, removing the noise. That is a cognitive financial signature of a high quality allocator. You see it in the actions before you see it in the results. Then you start seeing it in the results too.

The market has discarded Unity. I think that is the opportunity.

The same thinking led me to Uber. The market discarded it. After the recent results it is trading at 13 to 14 times free cash flow. I am betting on it because the capital allocator is exceptional, the moat is real, and the business economics are strong. That is again the same cognitive signature: go where the consensus has given up.

Howard Marks said it best. If you are in consensus, you will end up with mediocrity. Being contrarian is not about being different for the sake of it. It is about having done the work and arriving at a different conclusion than the crowd.

This same thread runs through every position I hold. Veeva, Bajaj Finance, and HEICO. Each one is a different geography, a different business type, a different industry. But in each case the capital allocator is what made the difference. You can have a great business and a poor allocator and still not compound at scale. The reverse is also true: a strong allocator inside a recovering or misunderstood business can give you outcomes the market hasn't priced in yet.

Someone asked me why I have not gone into Salesforce, which is such a larger company and can be a threat to Veeva Systems. The answer is simple. Billions and billions in reckless acquisitions, capital destroyed systematically over years. I know what the capital allocator of Veeva is trying to build. I have no such clarity with Salesforce. So I don't go there.

And if I cannot find a great allocator anywhere, I wait. I stay patient. I stay silent. But I will not put my money with a bad capital allocator no matter what. Not even 1%. Not even as a sector bet. Why would you shake hands with someone who is destroying capital?

It is like lending money to a friend who has never returned it and always has an excuse. You would not do it a second time. Now compare that friend to someone with a clean record, someone who has always been ethical, always returned what was yours, sometimes with more. That is the person you back. That is the capital allocator you back.

Most people obsess over the numbers. Numbers show you the past and the present. A strong capital allocator shapes what the numbers will look like three, five, ten years from now. If you cannot fully figure out the business model, you can figure out the person operating it. We are humans. I read a lot about psychology and human behavior because of that. The person running the business is a capital allocator. The person consuming the product is also a human being. Both matter, and both are readable if you pay attention to the right signals.

The filter is not complicated. The discipline to hold it is.

One last thing.

I can give you all the research. I can give you the thesis, the financial signature, the mental models. But the outcome will always depend on your own behavior and your own temperament. How you react when the position goes against you. How long you can hold something the market has discarded. Whether you trust the work you did or panic when the narrative shifts.

Always remember, you are the 100-bagger of your portfolio and your life. The research is just the beginning.

In case you missed it:

• Part 2: The One Ratio That Tells You When to Buy Gold and When to Go Aggressive on Stocks
• How a boring pharma exporter became a 50x compounder

u/SuperbPercentage8050 has already covered the cybersecurity space from the network and hardware side. This post is more focused on the software side of cybersecurity.

Every software application today needs to be tested for vulnerabilities, security gaps, and potential exploits before it goes into production. One trend I am seeing now is that developers are increasingly using AI to generate code. While AI definitely improves productivity, it can also introduce bugs, misconfigurations, and hidden security vulnerabilities that may go unnoticed during development.

Think about it this way. If a developer working at a company like J.P. Morgan ships code with a serious vulnerability and it slips through the cracks, a hacker can potentially exploit it and cause massive damage. These are not small issues. For large organizations, even a single vulnerability can lead to significant financial and reputational losses.

This is why penetration testing and security validation remain extremely important, especially for banks, fintechs, healthcare companies, and other highly regulated industries.

Some people may argue that AI tools and security models are becoming good enough to identify vulnerabilities on their own. While that may be true to some extent, I do not think companies will simply trust an AI model and call it a day. Most enterprises will still want an independent third party to validate their security posture. A specialized cybersecurity company also brings years of historical data, domain expertise, and practical understanding of how costly different vulnerabilities can be from a business perspective.

This is where TAC Infosec comes into the picture.

Unlike traditional service companies that send consultants to manually perform penetration testing, TAC is primarily a product-first cybersecurity company. Over the years, they have built multiple cybersecurity products, including:

• ESOF
• Socify
• CyberScope
• CyberSandia

ESOF

ESOF is their flagship platform. It includes multiple modules that help organizations identify vulnerabilities across web applications, mobile applications, cloud environments, APIs, and other digital assets.

Socify

This is one of the products that caught my attention.

If a startup or software company wants to sell its services to large US enterprises, obtaining SOC 2 compliance is often a necessity. Traditionally, this process involves third-party auditors and CPAs, takes several months, and costs a significant amount of money.

TAC is trying to solve this problem by reducing both cost and implementation time. From what I understand, the process can be completed in roughly 2 to 4 weeks at a much lower cost compared to many existing players.

Competitors generally charge anywhere between $10,000 and $20,000, whereas TAC's pricing is reportedly around $4,000, including CPA support. This pricing advantage could potentially be one of their major differentiators against established players like Vanta and others.

They have a few more products as well, but for now I am not focusing too much on them because they are still relatively small contributors. Maybe after a few more quarters they will become meaningful enough to discuss separately.

Now coming to the actual investment thesis.

For me, the biggest opportunity here is the reinvestment runway and the potential for cross-selling.

The company already has more than 10,000 customers and their average revenue per customer (RPC) is roughly $1,700. To me, this indicates a high-volume, low-ticket business model.

At this stage, customer acquisition itself does not look like the bottleneck because they already have a sizeable customer base. The real growth engine from here could be cross-selling.

For example, a customer may initially use one ESOF module for cloud security testing. Later, if the same customer needs web application testing, API security testing, compliance solutions, or other security products, TAC can potentially sell those solutions as well.

This is a playbook that many successful SaaS companies have followed over the years. As customers grow, their requirements also increase. A company that starts with two applications today may have five or six applications a year later. Naturally, their security requirements expand as well.

Once a customer enters the TAC ecosystem, the company gets multiple opportunities to increase wallet share over time.

Management's long-term vision is to reach around $10,000 in revenue per customer by 2030.

At first glance, that number may look ambitious and honestly I am still slightly skeptical about it. However, in businesses where cross-selling works effectively, acquiring the customer is usually the hardest part. Once that relationship is established, revenue expansion becomes much easier and can create a flywheel effect.

A somewhat similar pattern was seen with Shopify. Initially it was primarily an ecommerce platform. Over time they expanded into payments, shipping, POS, and several other offerings, increasing revenue from existing customers.

Whether TAC reaches $10,000 per customer or not remains to be seen, but the CEO appears very confident about the target.

What gives me some confidence is that the company has already increased revenue per customer from roughly $900 to around $1,700 within about 1.5 years.

This growth happened while they were simultaneously acquiring and integrating products such as CyberScope, Socify, SafeHouse, and others. So there is clearly some evidence that cross-selling is already happening.

Management has guided for approximately 20% half-yearly growth in revenue per customer and around 20% QoQ revenue growth. I would suggest everyone do their own modelling and see whether these targets appear achievable.

Coming to customers.

The company has worked with several large names, including Microsoft, Google, and recently management also mentioned Anthropic.

Now, having large customers does not necessarily mean these are massive contracts. But it does provide validation that the products are credible enough to be adopted by globally recognized organizations.

Interestingly, I think this also supports the argument that AI is not replacing cybersecurity.

If AI alone could solve security validation, why would an AI company like Anthropic require cybersecurity solutions from specialized vendors?

In fact, I would argue that as AI adoption increases, cybersecurity requirements may actually increase as well. Modern AI systems expose APIs, agents, connectors, integrations, MCP servers, and various external access points, all of which expand the attack surface.

More AI adoption could potentially mean more security checks rather than fewer.

Coming to valuation.

The stock is currently trading at around 37x earnings.

At first glance, that may seem expensive, but cybersecurity companies generally trade at premium valuations due to their growth potential and mission-critical nature.

The company currently generates ROCE of around 37% and net margins of approximately 40%, which are strong numbers in my view.

If management's FY27 guidance of ₹100 crore revenue and ₹40 crore PAT is achieved, then the forward valuation comes down meaningfully. By my estimates, that would imply roughly 25x FY27 earnings.

And if management ends up overdelivering, investors could see additional upside.

One more reason I started tracking this company was Vijay Kedia's investment. That initially got the stock onto my radar.

Around the same time, I also came across u/SuperbPercentage8050's posts, especially around cybersecurity mental models and bottleneck-based thinking, which helped me look at the business from a different angle.

Overall, this is my current high-level understanding of TAC Infosec. I could be wrong on several aspects, and there may be things I have missed.

Would love to hear views from people who track the cybersecurity space more closely or have a different perspective on the company. Constructive criticism is always welcome.

I've been working on a side project called Fathom over the last few weeks. (Link below)

The idea is pretty simple: I felt that a lot of stock research starts with financial ratios and ends with a buy/sell conclusion, but skips the part I find most interesting:

How does the business actually work?

So I'm trying to build a library that explains companies and industries from first principles.

For example:

• How does an FMCG company actually make money? For that matter any sector.
• Why does distribution matter more than the product in some businesses?
• What gives a company pricing power?
• Why can a company show profit but still have terrible cash flow?
• What actually happens to Indian companies when the RBI cuts rates?
• If crude oil gets cheaper, who actually gets to keep the saving?
• Why is a ₹10 lakh crore government capex announcement not the same thing as ₹10 lakh crore of revenue for infrastructure companies?

I've organized it into a few sections:

Companies — understand individual businesses
Sectors — understand how an entire industry works
Patterns — reusable business/financial mental models
Signals — take a real-world event and trace its impact through businesses
Case Studies — deeper dives into specific companies and situations
Reading Filings — learn how to actually extract information from annual reports and filings

One thing I'm trying to do differently with the Signals section is show the reasoning rather than just give the conclusion.

The background and motivation behind building this: I've been researching about companies myself since the past 4-5 years and my father has been doing this for nearly 2 decades. So I've put down my little learning plus his learnings from his old notes as a whole here. I admit I tried to refine and cross link the sections using AI as I would not be able to type all of this stuff out myself.

Link to Fathom - https://fathomjournal.in

I have been reading a lot of posts in this sub as well and our king u/SuperbPercentage8050's mental models and capillary's notes and tried to find correlation between our frameworks.

I'm still very much building this, and I'd genuinely like feedback from people who follow Indian businesses/stocks.

What would make something like this useful enough for you to actually bookmark and come back to?

I have used AI for articulation, that being said a couple of you from the community wanted an update from my end on IKS, so here it is with a couple of new lenses to look at IKS as well.

The Deal Is Done
The big one first. TruBridge closed on July 9. The main uncertainty I wrote about last time, whether the deal actually gets done, is now behind us. The bank syndicate funding was tied up in early August. So the acquisition is real and the clock on everything I described has started.

The Q1 Print
Q1 FY27 came out on August 6. Revenue was Rs 894 crore, up about 21 percent. PAT was Rs 194 crore, up about 28 percent. Profit growing faster than revenue again, so the operating leverage is still showing up in real numbers, not just in the slides.

One thing to keep in mind. This quarter is clean IKS only. TruBridge closed after the quarter ended, so none of it is in these numbers yet. The first combined picture comes in November.

One Change To My Earlier View
I had said margins were still in early innings. Q1 EBITDA came in around 33 percent and management is now guiding to sustainable margins in the early to mid 30s. So the way I read it now, margins are settling around here rather than climbing toward 40. That is not bad news. It just means the growth from here comes from revenue and TruBridge, not from margins expanding further. Worth being straight about that shift.

The Round Trip
Now the stock. Right after the deal closed it spiked to a new high near Rs 1,933. Then it drifted all the way back and it is around Rs 1,737 today. Classic buy the rumour, sell the news.

Here is the part I find interesting. The price is almost exactly where it was when I wrote the last post, but the biggest risk in that post, the deal closing, is gone. Same price, less risk. I will take that trade.

The leverage is now live and real, roughly 3x. Bringing that down from cash flow is the thing to track every quarter from here.

A couple of small items. They sold their Abridge AI stake for 10 million dollars. They set up a value based care arm to work with Medicare. And the chairman is retiring with a clean handover. None of these move the thesis on their own.

First, What Is Actually Being Bought And Sold Here
Before the lenses, let me explain the plumbing, because the whole thesis rests on it and it is easy to gloss over.

EHR is the hospital’s operating system. EHR stands for Electronic Health Record. It is the core software a hospital runs on. Every patient visit, diagnosis, medication, lab result, and doctor’s note gets entered into it. Doctors and nurses live inside it all day. TruBridge sells this software to about 700 rural hospitals. That is what IKS just bought.

RCM is the money side. RCM stands for Revenue Cycle Management. It is the paperwork chain that turns a treated patient into cash in the hospital’s bank account. A patient is treated, someone assigns the correct billing codes, a claim goes to the insurance company, the insurer pays, underpays, or rejects it, and then someone has to chase and fix the rejected ones until the hospital gets paid. That whole chain is RCM. This is what IKS is genuinely good at, coding and chasing claims, better and cheaper than a hospital can do itself.

Here is why owning the EHR matters. To do the billing work, RCM needs the clinical data of what happened to the patient. That data lives inside the EHR. So RCM always has to connect to the EHR. Normally an outside billing vendor has to build a bridge into whatever software the hospital uses. That bridge is slow, it breaks, data gets lost in transit, and the hospital’s IT team has to cooperate to make it work. That is the force-plugging-in problem, an outsider trying to wedge itself into someone else’s software.

IKS now owns the software. So when it sells its billing service into a TruBridge hospital, there is no bridge to build. The billing engine reads directly from the same system the doctors are already typing into. No doorway, no data lost, no waiting on a third party. IKS used to be the outsider integrating into everyone else’s system. For these 700 hospitals, it now is the system. That is the entire edge in one line. It is not knocking on the door asking to be let in. It already owns the house and is adding a room.

Looking At It Through Five Lenses
Since the deal is real, the question is no longer will it close. It is will the cross sell work. So instead of one big number, I break the thesis into five separate ways it can win or lose, each with its own thing to watch.

The setup in one line: TruBridge sells software to 700 rural hospitals. About 450 of them use that software but do not buy reliable billing work from anyone. IKS now owns the software. The job is simple to say and hard to do, walk into those 450 hospitals, who are already customers, and sell them the billing and clinical work IKS is good at. The customer is already inside the house.

Lens 1: The Customer Economics
This is the strongest lens. Owning the front door is a real, durable edge, and the risk here is not whether hospitals say yes. It is how fast the work actually goes live. Selling billing into your own software is far easier than a stranger plugging in from outside. The friction is not sales. It is plumbing. Hospital IT teams move slowly, and credentialing, training, and setup can drag. If conversions lag, the debt keeps costing money while the new revenue takes its time. So watch the speed of go-live, not the number of handshakes.

On the size of the prize, I am going to be more conservative than the excited version of this. TruBridge’s existing billing business does roughly 220 million dollars across 250 to 300 hospitals, which is about 0.7 to 0.9 million per hospital, and that is for hospitals already buying. The 450 whitespace hospitals are the ones that did not buy, which likely means smaller or more reluctant. So I use 0.6 to 0.8 million per hospital, not a full million. Convert a fifth of the 450, so 90 hospitals, and that is roughly 55 to 70 million dollars of high margin revenue with almost no cost to win it. Still very good. Just not the shinier number you will see floated around.

Lens 2: The Rural Hospital Reality
IKS is selling to rural and community hospitals, and many of them are barely surviving. More than half run at a loss. They cannot find or afford admin staff. For them IKS is a lifeline that keeps cash coming in, not a nice-to-have. That distress creates urgency and speeds up deals once a conversation is serious.

But I want to be honest that distress cuts both ways, because the excited version only shows the good half. A desperate hospital is a motivated buyer with a weak balance sheet. Some of them will close, and a closed hospital is not a customer. The ones that survive negotiate hard and pay slowly. So yes, urgency is real, but distressed also means churn risk and pricing pressure. It is a tailwind and a hazard at the same time.

There is a second real driver here. Big insurers are using software to auto-reject hospital claims. Small hospitals have no way to fight back. IKS becomes their outsourced defense, getting them paid on claims they would otherwise lose. That is an easy thing to sell to someone bleeding cash.

Lens 3: The Labor Arbitrage Engine
This is the quiet engine under everything, and it is the most durable of the five. Admin and coding staff in the US are scarce and expensive and getting more so. IKS does that work from India at a fraction of the cost, at scale. A local US competitor cannot match that cost base. That gap is the whole model.

There is a small currency helper too. IKS earns in dollars and pays a chunk of its costs in rupees, and the rupee tends to drift weaker over long stretches, which pads the margin in the background. I treat this as a mild, unreliable cushion, not something to bank on. It can reverse for years. Nice to have, not a driver.

Lens 4: The Integration Risk
This is the real risk in the whole thesis, and I weight it heavier than most people do. Demand is the easy part. Execution is the hard part.

TruBridge was a slow, old-style software company. IKS is fast and execution heavy. Bolting a slow culture onto a fast one is where most of these deals quietly break. On top of that, healthcare data systems are wrapped in compliance rules, and merging them takes longer than anyone hopes. If the deep integration takes 18 months instead of 6, the debt keeps ticking the whole time and the returns get pushed out.

Put plainly, if this trade goes wrong, this is probably the lens where it goes wrong. Not demand, not the size of the market. Execution on a base IKS has not run before. The market is giving IKS credit for an integration it has not shown yet on these specific hospitals.

Lens 5: The Debt Math
This lens changes how the returns actually get made, and it is worth understanding. The company took on about 600 million dollars of debt, roughly 3x. Normally you think returns come from the business growing or the multiple going up. Here, a big chunk of the next few years of return can come simply from paying that debt down. As the combined company throws off cash and kills the debt, value quietly shifts from the lenders to the shareholders even if nothing else changes. Boring, but it is real money, and most people miss it.

Now tie it to the margin point from earlier. I do not read the margin guide dropping from 40 to the mid 30s as a warning about hidden costs. The simpler and more likely reason is just mix. TruBridge is a lower margin, more people-heavy legacy business, so bolting it on mechanically drags the blended margin down toward the mid 30s. That is arithmetic, not a red flag. The takeaway still holds though. I am no longer buying a margins-keep-climbing story. I am buying a get-those-450-hospitals-converted story. The win comes from volume of hospitals, not from the margin line stretching higher.

The Sixth Thing, Hiding Under All Five
There is one assumption none of the lenses names, and it is the honest bear case, so I want it on the table.
Every lens quietly assumes IKS can run TruBridge’s billing work at IKS economics. But TruBridge’s own billing business currently uses about 3,500 people. The entire thesis is that IKS’s tech-led model does that work with a fraction of the headcount. That transformation is assumed, not proven. If IKS converts the 450 hospitals but cannot strip out the labor and lift the margin, you get the revenue without the profit, and the whole return math softens.
So the real question under all five lenses is not just will hospitals convert. It is will they convert AND will IKS run them at its own margins, not TruBridge’s. Both have to be true.

The one reason I lean toward believing the second half happens, IKS has already done exactly this once, with the AQuity acquisition, and did it ahead of schedule. That is a real track record on the exact skill in question. But it is a reason to believe, not proof it has happened here yet. November is where I start finding out.

What Ties It All Together
Every one of these lenses points at the same single number. How many of those 450 hospitals actually start moving into IKS billing and clinical work, and whether IKS runs them at its own margins once they do. The lenses just tell you the different reasons it will or will not happen. Customer economics says the door is open. The rural reality says the customers are motivated but fragile. The labor engine says the economics work. Integration risk and the debt clock say do not take the speed for granted. And the sixth point says converting them and running them profitably are two separate bets.

The first real read is the November concall, the first set of numbers with TruBridge inside them. That is the print that tells us whether this worked.

Where I Stand
Unchanged. Still holding. Not chasing it here at 39 times earnings. I add on weakness, or when the cross sell actually shows up in the numbers, not before.
Not financial advice. I hold a position. Do your own work.

Business model

Sigachi operates predominantly across three segments:

Excipients (Microcrystalline Cellulose / MCC): core business; used as binder/disintegrant in pharma formulations; also used across multiple end markets.Sold under prominent brand names like HiCel and AceCel.[75-80%revenue]

O&M (Operations & Management services): Asset light- operates other companies factories , company earns based on outpout of the factory. steady contributor; clients includes birla, adani solar etc,[10-12% revenue]

API initiatives: acquisition of an 80% majority stake in Trimax Bio Sciences Private Limited. building API, R&D + regulated market readiness; CEP filing work [10% revenue]

Competitive Moats & Operational Strengths

​Global Scale in MCC: Sigachi operates with an aggregate MCC production capacity approaching 30,000 MTPA(targeted fpr Q427, current 18000MTPA,) making it the largest manufacturer in India and a top-tier supplier globally.

​Stringent Regulatory Accreditations: Facilities hold approvals from major global bodies (including US FDA, EDQM, EXCiPACT, ISO, Halal, and Kosher), creating high switching costs for pharmaceutical clients who cannot easily alter their approved drug formulations.

Global Exports: exports contribute 60% revenue , exports to 60+ countries

Growth Drivers & Capex Blueprint

​1. Capacity Expansion in Core Excipients

​Dahej SEZ Expansion: Sigachi has deployed capital to expand its Dahej manufacturing facility, adding new production lines to capture growing export demand in regulated Western markets.

​In-house R&D: Development of specialized grades of MCC (high-density, low-moisture, co-processed excipients) that command higher realizations than standard powder grades.

​2. Forward Integration into APIs

​To reduce dependence on single-product cycles, Sigachi is expanding into API manufacturing through trimax bio acquistion(80%) leveraging its existing global B2B distribution network.(expanding from 100 KL to 250 KL) and ongoing filings for European CEP certifications.

​3. Shift Toward High-Margin Specialty-CCS

​Increasing the revenue share of specialty blends (CCS) which has better margins (20%+)

​Key Investment Risks & Challenges

​Raw Material Price Volatility: Primary raw materials—wood pulp and specialty cotton linter—are tied to global commodity prices and import freight rates. Spike in pulp costs directly squeezes gross margins.

​Product Concentration: Despite diversification attempts, a significant majority of total revenues still originate from MCC and cellulose derivatives. (80%)

​Execution Risk on API Pivot: Transitioning from an excipient vendor to an API and custom synthesis manufacturer involves distinct regulatory, technological, and marketing hurdles.

The revenue decline and loss from the last year is an one time off due to fire accident hsppened in hyderabad plant. Where whole plant got destroyed and 40 people died.which caused one time spending of 100+ crores and management said around 60crs revenue due to loss of hyd capacity.

The company is yet to receive insurance amount which is a good sign

Management expects 650 -670 crs revenue in 2027 with margin around 18% .

Please give your view on sigachi, would love to hear your opinions

Hi pls add your opinions in comments. Wanted to know your views

Since eClerx has already been covered in this channel I'll jump straight into Q1 results

https://www.reddit.com/r/IndiaGrowthStocks/s/sR9JUqzUm6

Disclaimer - took help of AI

OCF Q1 FY27: ₹1,073mn vs PAT ₹1,643mn → CFO < PAT this quarter.

the CFO/EBITDA conversion ratio is just 37.9%, far below the 62–75% annual norm. The reason is explicit and structural: Q1 always sees annual variable pay disbursements for the prior year. This is a seasonal mechanical pattern, not a quality deterioration. It has repeated every Q1 for years.

Monitor Q2 OCF — must recover toward 70%+ conversion.

Attrition: Offshore voluntary attrition improved sharply to 18.1% from 21.7% in Q4.

Revenue grew 2.8% QoQ in USD. The business did not slow — costs stepped up in one quarter due to the annual wage cycle. Every BPO in India shows this Q1 pattern.

The EBITDA margin of 23% is actually at the floor of management's guided range of 24–28%. Q2 onwards, with no fresh wage hike, operating leverage should kick in as revenue grows sequentially.

Revenue: 12th consecutive quarter of sequential USD growth. This is an exceptional streak for a company of this size and maturity.

ACV of new deals: $41mn, up 25% YoY. New deal wins are the leading indicator — revenue converts from deals with a 1–4 quarter lag. The ACV has nearly doubled in two years. The revenue engine is loading.

Analytics & Automation: Crossed $100mn annual run rate, grew 7% sequentially vs company average of 2.8%. The highest-margin, highest-value segment is growing fastest.

Emerging verticals: Now 11.7% of revenue mix vs 8.4% in FY26 — F&A, high-tech, and emerging geographies building momentum.

BFSI: Down from 40.8% to 37.6% of mix — still the largest vertical but losing share. Management says H2 recovery as pipeline converts. This is the key thesis risk to monitor.

Tech Services headcount: 2,261 vs 2,109 last quarter — 7.2% sequential increase. This is investment in AI capability ahead of demand. It's a cost now, revenue later pattern.

Annualised Q1 EPS: ₹17.86 × 4 = ~₹71.4 (but Q1 is always margin-suppressed due to wage cycle)

Better to use: FY26 PAT = ₹7,062mn on ~9.41Cr shares = FY26 EPS ₹75 as base, with Q1 showing the trough of the annual cycle.

FY27 EPS estimate: If margins recover to 25% EBITDA average for the year (guidance midpoint is 26%), and revenue grows ~15% YoY in USD on INR terms ~23%:

FY27E Revenue: ~₹50,000mn (conservative)

EBITDA at 25.5%: ~₹12,750mn

PAT at ~14.5% margin: ~₹7,250mn

EPS: ~₹77 (modest growth vs FY26's ₹75–76)

The EPS growth will look modest in FY27 purely because Q1 is depressed and the agentic AI deal revenue starts only Q4 FY27. FY28 is where the earnings acceleration appears on the P&L.

Since I classify it as a hybrid platform business, PE well below the Hybrid Type 1 ceiling of 35–38x.

Ex-cash P/E = (1872-137)/75 = 21.88x. Cheap imo.

EPS Engine: ⚠️ Temporarily pressured but structurally intact

P/E Engine: ⚠️ Still compressed but recovering

The hedge table is outstanding insight

Current spot INR/USD is ~94.5. eClerx is hedged well below spot for the rest of FY27, meaning as each quarter rolls, they get better realisation than the last. By Q4 FY27, they'll realize ₹92 vs ₹88 in Q1 — a 4.2% revenue tailwind just from FX rolling through. This is an automatic margin booster that requires zero operational effort.

Bottom line: This is a typical "Q1 seasonal trough + wage reset" quarter.

Disclaimer - I am holding this stock for a long time now and I've added some today as well. If it continues falling, I'll buy again at around 1650.